Clinical Trials Logo

Filter by:
NCT ID: NCT06084286 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Start date: October 30, 2023
Phase: Phase 1
Study type: Interventional

Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer. The CLDN18.2/PD-L1 dual-targeting CAR-T will be investigated in patients with CLDN18.2-positive advance solid tumors.

NCT ID: NCT06084156 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study to Evaluate the DDI of HSK7653 With Metformin

Start date: August 10, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single center, open-label, single arm, drug-drug interaction study of HSK7653 and metformin in Healthy Subjects.

NCT ID: NCT06084000 Recruiting - Drug-coated Balloon Clinical Trials

STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial

STENTLESS
Start date: October 15, 2023
Phase: N/A
Study type: Interventional

This is a multicenter, open-label, randomized controlled study meant to compare the safety and efficacy of scheduled drug-coated balloon (DCB) and conventional drug-eluting stent (DES) strategy in the treatment of de novo lesions of large coronary vessel with diameter larger than 2.75 mm. The trial was designed to provide high-quality evidence for expanding the clinical indications of DCB, and to explore a better way for coronary intervention based on DCB.

NCT ID: NCT06083870 Recruiting - Clinical trials for Non-small Cell Lung Cancer Metastatic

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Start date: December 13, 2023
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.

NCT ID: NCT06083831 Recruiting - Critical Illness Clinical Trials

The Effect of Sequential Feeding for Circadian Rhythm and Gut Flora Rhythm in Critically Ill Patients

Start date: October 7, 2023
Phase:
Study type: Observational

Circadian rhythms plays an important role for healthy. And critical illness contributes to the disruption of circadian rhythms. Not only right but also feeding can affect the circadian clock gene expression. In a investigators' previous study, some metabolic indicators (the albumin level, total cholesterol level and total bile acid level) and the increases in lymphocyte counts in the sequential feeding group were different from those in the continuous feeding group. Investigators think sequential feeding may adjust circadian clock gene expression for its effect on metabolism and immunity. Moreover, sequential feeding did alter the abundances of some gut microbes to some degree in the investigators' previous study. Investigators think sequential feeding may adjust gut flora rhythms.

NCT ID: NCT06083779 Recruiting - Endometrial Cancer Clinical Trials

Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics

Start date: August 1, 2023
Phase:
Study type: Observational

The purpose of this study is to enable non-invasive early detection of endometrial cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage endometrial cancer patients and healthy individuals will be subjected to whole-genome sequencing. Five different feature types, including Fragment Size Distribution, nucleosome features, SBS Signatures, BreakPoint Motif , and Copy Number Variation will be assessed to generate this model.

NCT ID: NCT06083701 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study

Start date: September 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono-therapy in PTCL. The combination of duvelisib and romidepsin is highly active for relapsed and refractory PTCLs. The aim of this study is to further explore the efficacy and safety of HDAC inhibitor chidamide combined with PI3K inhibitor linperlisib in the treatment of relapsed and refractory PTCLs.

NCT ID: NCT06083623 Not yet recruiting - Clinical trials for Respiratory Syncytial Virus Infections

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Start date: October 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), neutralizing antibody and antidrug antibody (ADA) response for TNM001 in infants entering their first RSV season.

NCT ID: NCT06083532 Recruiting - Physical Fitness Clinical Trials

Effect of PAP on Lower Limb Explosive Force in Basketball Players in CHINA

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

The phenomenon that high-intensity warm-up activities help improve muscle strength and explosive performance is called post-activation potentiation (PAP), which is a warm-up method that uses high-intensity stimulation to induce the activation of more type II muscle fibers. However, the results of studies exploring the enhancing effect of PAP on lower limb explosive strength are still controversial. In studies with no significant difference, it is believed that there are many factors that affect PAP, such as activation method, activation intensity, recovery time and individual factors, etc., and it is difficult to control during implementation. In addition, traditional warm-up methods such as jogging and stretching have been shown to have limited effectiveness in improving athletes' performance. In the past, there have been many studies on the combination of PAP and lower limb explosive strength, but there are almost no studies on the long-term effects of PAP on the lower limb explosive strength of basketball players. Therefore, this study studies the characteristics of PAP in order to find the best activation scheme for PAP, and then combines the enhancement effect of PAP with the explosive power of the lower limbs to improve the explosive power of the lower limbs of basketball players, and verifies the long-term effect of combining PAP with explosive power training. In order to provide new changes and breakthroughs in the design of physical training for basketball players and improve the sports performance of college male basketball players.

NCT ID: NCT06083350 Active, not recruiting - Alzheimer Disease Clinical Trials

Effects of Yeast Beta-glucan on Cognitive Function in Patients With Mild Cognitive Impairment

Start date: June 27, 2023
Phase: N/A
Study type: Interventional

Patients with mild cognitive impairment aged 50-80 years old were recruited in Shiyan City, Hubei Province, and divided into intervention group and placebo group. They were given yeast β-glucan capsules and starch capsules, respectively, for 6 months, in order to explore whether yeast β-glucan can improve cognitive function of patients with mild cognitive impairment by regulating gut microbiota and its metabolites.